Highly Pure GM1 Ganglioside Composition for Therapeutic Formulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing ganglioside preparations, whether isolated from biological sources or prepared through chemo-enzymatic synthesis, are significantly less than 95% pure with respect to GM1 content, and are contaminated with other gangliosides and ceramide analogues, complicating therapeutic use and regulatory approval.
Innovation Solution
The development of a highly pure and structurally homogeneous ganglioside composition, specifically GM1, achieved through a combined enzymatic and chemical synthesis method, resulting in a purity of at least 96% and a substantial absence of (Gal)n moieties, with the ability to formulate into highly concentrated, clear, aqueous solutions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If gangliosides are isolated from biological sources, then the production process is established, but the purity of GM1 is significantly less than 95% and contaminated with other gangliosides and ceramide analogues
Solution Approach 1:
The patent segments the complex biological mixture into individual ganglioside species through systematic purification steps. HPLC chromatography separates GM1 from other gangliosides (GM2, GM3, GD1a, etc.) and ceramide analogues by exploiting differences in their molecular structures and affinities for the stationary phase, achieving greater than 95% purity of GM1
Solution Approach 2:
The patent extracts the desired GM1 ganglioside from the complex biological source material by selectively isolating it through chromatographic techniques. The extraction process removes contaminating substances including other ganglioside species and ceramide analogues, leaving behind highly purified GM1 suitable for therapeutic use
2Quantity of substance
If chemo-enzymatic synthesis is used to prepare gangliosides, then production is achieved, but the purity is significantly less than 95% with contamination by other gangliosides
Solution Approach 1:
The patent employs HPLC chromatography as an intermediary purification step between synthesis and final product. This intermediary process separates the desired GM1 product from side-products and contaminating gangliosides generated during chemo-enzymatic synthesis, achieving greater than 95% purity
Solution Approach 2:
The patent optimizes synthesis parameters including enzyme concentrations, substrate ratios, reaction temperatures, and pH conditions to maximize GM1 yield while minimizing formation of other ganglioside species. These parameter changes enable selective production of GM1 over contaminating species
3Quantity of substance
If complex isolation and purification procedures are used, then purity is improved, but the process complexity and regulatory approval difficulty increase
Solution Approach 1:
The patent performs preliminary enrichment of GM1 from the complex biological source or synthesis mixture before final purification. This preliminary action concentrates the target ganglioside and reduces the burden on subsequent purification steps, simplifying the overall process while maintaining greater than 95% purity
Solution Approach 2:
The patent replaces complex mechanical separation techniques with HPLC chromatography, which provides more efficient and selective separation based on molecular properties. This substitution simplifies the purification process while achieving superior purity levels compared to traditional mechanical methods
Data Source
AI summary
Highly pure, highly homogeneous ganglioside compositions are provided in addition to methods of making and using these compositions. An exemplary ganglioside composition is a GM1 composition.